‼️ #ctDNA26 simultaneous publication by Zhao et al: Beyond ctDNA for Efficacy: Can We Use cfDNA to Detect and Monitor Toxicity Signals? Read the full article here: https://bit.ly/4fw4dsB

⏰ Attending #ASCO26? Join #JCO Journals editors and editorial board members for one-on-one mentoring in JCO Central. Attendees interested in publishing may sign up for a 25-minute situational mentoring session. Sign-ups close tomorrow, May 21, at 11:59 PM (ET). Sign up today: https://bit.ly/4drDfzC

Recently published: 340B Drug Pricing Program: An Updated @ascocancer.bsky.social Policy Statement https://ascopubs.org/doi/10.1200/OP-26-00105

Listen to the latest #ASCO #JCO Cancer Stories: The Art of Oncology episode "The Liver We Share” by Ryan Wexler. After encountering a hepatectomy as a medical student, his journey comes full circle as he becomes a living liver donor for his wife: https://bit.ly/4cQ8e8f @mikkaelsekeres.bsky.social

Don’t miss out on the 10th Anniversary TAPUR Grand Rounds! Join the onc community May 12 for the Fourth Annual TAPUR Virtual Grand Rounds. As we celebrate 10 yrs of advancing precision medicine, this is your chance to hear directly from founding #TAPUR experts. Register today: https://bit.ly/485rXza

Cancer risk isn’t just about age. A study of 450K people shows lifetime risk varies by up to 2x between individuals. Age-only screening misses high-risk patients and overtests low-risk ones. The future? Personalized, risk-based screening. Read the full article: https://bit.ly/4dYankA

Check out the latest #TAPUR study paper in #JCOPO: Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Read the full article: https://bit.ly/4cVvaUU

#ASCOConnection covers a new special series in #JCOCCI that explores the practical application of large language models (LLMs) and their impact on #CancerCare delivery. Read more: https://connection.asco.org/do/navigating-opportunities-and-challenges-large-language-models-oncology #LLM

JCO Precision Oncology would like to welcome our newest Associate Editor Matthew B. Yurgelun, MD, of Dana-Farber Cancer Institute, Boston, Mass. #JCOPO @mattyurgelun.bsky.social#JCOPO

PREDICT trial in #mCRPC takes precision onc a step further, integrating DNA + RNA profiling, molecular tumor boards & adaptive Tx allocation. Importantly, pts can be re-assigned at progression based on updated tumor biology--a move toward truly dynamic cancer care. Read more: https://bit.ly/4sZA8FH

#JCO welcomes as our newest Associate Editor Dr. Brigette Ma at the Prince of Wales Hospital, The Chinese University of Hong Kong. Welcome, Dr. Ma!

A new original report in #JCOPO provides valuables insights into the genomic landscape and prognostic biomarkers of advanced ESCC, which can guide future research toward more reliable biomarkers and targeted strategies. Read the article: https://ascopubs.org/doi/10.1200/PO-25-00971 #esocsm

JCO Global Oncology welcomes new Associate Editor Haneen Abaza, MSc, ACRP-CP, from King Hussein Cancer Center!

The Art of Global Oncology series in #JCOGO provides a vital space for narratives that focus on the experience of living with cancer and caring for patients with cancer. Check out the latest Art of Global Oncology paper, "Maps, Scars, and the Miles Between": https://bit.ly/47uZlz9

We are proud to introduce our latest collection, Special Series: Large Language Models. The papers in this series discuss the practical application of LLMs, their impact on cancer care delivery, and the ethical & practical implications of these AI systems: https://bit.ly/4upseqn

JCO is seeking a clinical investigator and leader to serve as its next Editor-in-Chief. Submit your interest today to advance @ASCO’s flagship & highly cited publication. Interest forms due March 9. Apply: https://bit.ly/3ZyIzuF

JCO is seeking a clinical investigator and leader to serve as its next Editor-in-Chief. Submit your interest today to advance ASCO’s flagship & highly cited publication. Submit your interest today: https://app.smartsheet.com/b/form/2448e4c7b7c34af69ff735a11affb305

‼️#GU26 simultaneous publication by @AarmstrongDuke et al:  Trial Design and Objectives for Patients with Prostate Cancer: Recommendations From Prostate Cancer Working Group 4 Learn more: https://bit.ly/46dupmq

We are proud to name Zsofia Stadler, MD from @mskcancercenter.bsky.social the next Editor-in-Chief of JCO Precision Oncology starting July 1st. Dr. Stadler’s expertise will drive the integration of genomics & AI into cancer research for improved patient outcomes. Read more: bit.ly/4aoLPyZ #JCOPO

Dr. Pedro Barata of University Hospitals Seidman Cancer Center and Dr. Ugwuji Maduekwe of the Medical College of Wisconsin discuss the emergence of organ preservation in GEJ and gastric cancers on the latest episode of the ASCO Education #BytheBook Podcast. Listen here: https://bit.ly/4tAUje4

JCO Global Oncology (JCO GO) guest editors Drs. Fabio Ynoe de Moraes & Paul Pearlman discuss JCO GO's Special Series featuring the investigators working to develop a new generation of innovations through the NCI’s Affordable Cancer Technologies Program. Read more: https://bit.ly/4tr3vl9

The draft guideline update for "Breast Cancer Follow-Up After Primary Treatment" is now available. Help us refine these standards of care. Submit your feedback to @ascocancer.bsky.social by February 23! Read & comment here: https://bit.ly/4ccwl2h #bcsm #BreastCancer

Big news! Onyinye D. Balogun, MD, MSc joins JCO Global Oncology as the new Associate Editor! We’re excited to have her expertise from @northwellhealth.bsky.social. Welcome, Dr. Balogun! #JCOGO #GlobalOncology

We are thrilled to announce that Dr. Chiara Cremolini is joining the Journal of Clinical Oncology (JCO) as our newest Associate Editor! Her expertise in colorectal oncology & clinical and translational research aligns perfectly with our mission to advance cancer care.

New #ASCO #JCO Cancer Stories: "A Chance to Heal with Cold Hard Steel" with host @mikkaelsekeres.bsky.social#ASCO#JCODr. Taylor Goodstein shares a powerful perspective on surgery, grief, and finding courage within our own fallibility. Tune in: https://bit.ly/4rG0nQL

JCO Updated Stage IV NSCLC guidelines: ➡️ASCO Living Guideline: Stage IV NSCLC (With Drivers) https://bit.ly/49SWlye ➡️ASCO Living Guideline: Stage IV NSCLC (Without Drivers) https://bit.ly/4at28L1

Exciting news! Fabio Ynoe de Moraes, MD, PhD, MBA, of Queen’s University has been named Deputy Editor of JCO Global Oncology. Dr. Moraes’ leadership will drive #JCOGO’s mission to improve cancer care access and equity worldwide. Join us in congratulating Dr. Moraes! #GlobalOncology

#Telehealth has been a huge boon to oncology: save pts time, see people who might not be able to travel. Q in new study @jco-asco.bsky.social: is "webside manner" affecting quality? Are we just adding extra appts? A: Largely, no! Similar communication, slight ⬆️ appts. ascopubs.org/doi/full/10....

We are thrilled to welcome Dr. Hsu as the new Editor-in-Chief of the ASCO Educational Book. A leader at UCSF and the San Francisco VA, Dr. Hsu aims to evolve the journal by embracing new formats to contextualize emerging oncology discoveries. Welcome!

In the latest #JCO Cancer Stories with host Dr. @mikkaelsekeres.bsky.social#JCO Dr. Henry Bair shares a moving account of how vision care can honor end-of-life goals—helping a patient with failing sight write to his children. Listen here: https://bit.ly/3ZxVYD9 #ArtOfOncology

When an oncologist leaves a rural community, the vacancy is more than a line item on a HR report. A new #JCOOP study explores the repercussions of specialist scarcity. Listen to the full podcast with @fumikochino.bsky.social, Dr. Erika Moen & Dr. Dan Zuckerman: ascopubs.org/do/understaf...

New @ascocancer.bsky.social mCRPC living guideline updated recommendations for systemic therapy are here! For patients w/ visceral metastases (lung/liver), enzalutamide or docetaxel is advised, regardless of HRR status. Stay current on mCRPC care: brnw.ch/21wZfuI

Check out JCO Precision Oncology's new TAPUR Study Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry. Learn more: brnw.ch/21wZ9I0

Here is our publication in @jco-asco.bsky.social! We describe how common medications impact immunotherapy, how this affects practice and patients today, and outline ways to leverage this knowledge toward improved patient as well as our understanding of tumor immunology. ascopubs.org/doi/10.1200/...

Attending ASCO #GI26? Join the Pathways to Publication Luncheon to meet the JCO Journals editorial team. Get tips on peer review & publishing your manuscript. Limited space—first come, first served! 📅 Jan 9 | 11:45 AM PT | Level 3, Room 3005

Just published in #JCO, @jmikhaelmd.bsky.social & @lisakhicks.bsky.social introduce a new @ascocancer.bsky.social living guideline w/ updated recommendations for multiple myeloma therapy in differing variants and pt populations. Learn more: brnw.ch/21wYSoe

Patil et al’s phase II study of seribantumab in tumors harboring NRG1 fusions supports the anti-tumor activity and safety of seribantumab in patients with advanced solid tumors harboring NRG1 fusions. Read the full article. ascopubs.org/doi/abs/10.1...

Nassar et al’s study demonstrates high concordance of Recurrence Score® (RS) results between paired core needle biopsy (CNB) and surgical excision (SE) samples, which supports use of CNB for Oncotype DX® testing. Read the full article. ascopubs.org/doi/abs/10.1... #BreastCancer #bcsm

Listen to the latest #ASCO #JCO Cancer Stories: The Art of Oncology with host @mikkaelsekeres.bsky.social. In this episode "Smell” with Dr. Cusick shares a connection to a cancer patient manifested as a scent. 🎧: ascopubs.org/do/smell-sce...

Simultaneous publication at #SABCS25! Horimoto et al.'s real-world data explores the clinical relevance of HER2 mutations in the efficacy of Trastuzumab Deruxtecan for HER2-low metastatic breast cancer. 👉 See the analysis: ascopubs.org/doi/abs/10.1... #BreastCancer

🚨 HER2+ MBC Maintenance News! 🚨 The Phase 3 HER2CLIMB-05 trial (Dieras et al.) was simultaneously published at #SABCS25. This study assesses Tucatinib vs. Placebo with Trastuzumab/Pertuzumab as first-line maintenance. 👉 See the results: ascopubs.org/doi/abs/10.1... #HER2Positive #BreastCancer

🎧 New #JCOAfterHours episode! Dr. Davide Soldato sits down with Dr. Andrea Necchi & Dr. Ashish Kamat to discuss their @ascocancer.bsky.social article on evolving end points for non-operative #MIBC trials and bladder-sparing strategies. Listen here: ascopubs.org/do/milan-con...

New data may reshape early-stage Triple-Negative Breast Cancer (TNBC) care! Simultaneous publication at #SABCS25: The Phase III RJBC 1501 trial (Shen et al.) confirms/challenges the role of Carboplatin in adjuvant EC Taxane. 👉 Read the results: ascopubs.org/doi/abs/10.1... #TNBC #BreastCancer

🚨 NEW DATA ALERT! 🚨 The Phase III BRUIN CLL-313 trial (Pirtobrutinib vs. BR) in untreated CLL/SLL was presented for simultaneous publication at #ASH25! You won't want to miss this! Learn more: ascopubs.org/doi/abs/10.1... #CLL #SLL

“Multidisciplinary care for a patient who's diagnosed with cancer while pregnant is essential.” In this “Science in Seconds,” Dr. Ann Partridge & Dr. Alison Loren discuss our first guideline on cancer during pregnancy. Read the guideline in @jco-asco.bsky.social: brnw.ch/21wYhKr

The first-ever Phase III randomized showdown is here! See results of pirtobrutinib vs. ibrutinib in treatment-naïve and R/R patients. Is the non-covalent BTKi the game-changer we’ve waited for? #ASH25 simultaneous publication with Woyach et al. is LIVE: brnw.ch/21wYbdz

The new AL International Staging System (AL-ISS) is here, defining Stage IIIC as an ultra-poor risk. Simultaneous publication at #ASH25! This is a major step for diagnosis and patient care. 👉 Read the full abstract: brnw.ch/21wYb73 #ALamyloidosis #Hematology

Pennsylvania Farmers & Skin Health: Unpacking the link between specific agricultural practices and melanoma incidence in the Keystone State. Learn more: brnw.ch/21wXMUK

"I was lucky. I had good insurance, I lived in LA, I was treated at 4 big cancer centers.   I speak to patients who if they don't go to work today, they don't get a paycheck. They can't miss a day to travel 8 hours to go see a specialist." 🎙️New @ascocancer.bsky.social @jco-asco.bsky.social podcast:

Check out #JCOGO's new article, discussing implementation of geriatric assessment in resource-constrained settings and some outstanding implementation questions and concerns. Learn more: brnw.ch/21wXieA